Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR1733 in advanced cancers
NCT05749549Phase 2Active, not recruiting
- Sponsor
- Shanghai Blueray Biopharma Co., Ltd.
- Start
- Apr 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BR1733 in follicular lymphoma (FL), peripheral T-cell lymphoma (PTCL), diffuse large B-cell lymphoma (DLBCL), solid tumor, sponsored by Shanghai Blueray Biopharma Co., Ltd.. Started Apr 2023; status: active, not recruiting.
02
Drugs
BR1733
03
Conditions
follicular lymphoma (FL)peripheral T-cell lymphoma (PTCL)diffuse large B-cell lymphoma (DLBCL)solid tumor
Beyond the preview
Go deeper on NCT05749549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05749549.